Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Objectives Hypofunction of NMDA receptor is implicated in the pathophysiology, particularly cognitive impairment, of schizophrenia. Sarcosine, a glycine transporter I (GlyT-1) inhibitor, and sodium benzoate, a d-amino acid oxidase (DAAO) inhibitor, can both enhance NMDA receptor-mediated neurotransmission. We proposed simultaneously inhibiting DAAO and GlyT-1 may be more effective than inhibition of either in improving the cognitive and global functioning of schizophrenia patients. Methods This study compared add-on sarcosine (2 g/day) plus benzoate (1 g/day) vs. sarcosine (2 g/day) for the clinical symptoms, as well as the cognitive and global functioning, of chronic schizophrenia patients in a 12-week, double-blind, randomised, placebo-controlled trial. Participants were measured with the Positive and Negative Syndrome Scale and the Global Assessment of Functioning Scale every 3 weeks. Seven cognitive domains, recommended by the Measurement and Treatment Research to Improve Cognition in Schizophrenia Committee, were measured at weeks 0 and 12. Results Adjunctive sarcosine plus benzoate, but not sarcosine alone, improved the cognitive and global functioning of patients with schizophrenia, even when their clinical symptoms had not improved. Conclusions This finding suggests N-methyl-d-aspartate receptor-enhancement therapy can improve the cognitive function of patients with schizophrenia, further indicating this pro-cognitive effect can be primary without improvement in clinical symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-speed scanning in human memory
Sternberg, S. (1966) · Science · doi:10.1126/science.153.3736.652 · Cited by 3,576
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 3×
“…of schizophrenia (Krystal et al. 1994; Sawa 2009; Javitt et al. 2012; Errico et al. 2013) suggests that enhancement of the NMDA receptor function may improve the cognitive impairment of schizophrenia (Krystal et al. 1994; Javitt et al. 2012; Hashimoto et al. 2013; Paoletti et al. 2013).”
BackgroundResultGreen, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523 · cited 2×
“…of schizophrenia (Krystal et al. 1994; Sawa 2009; Javitt et al. 2012; Errico et al. 2013) suggests that enhancement of the NMDA receptor function may improve the cognitive impairment of schizophrenia (Krystal et al. 1994; Javitt et al. 2012; Hashimoto et al. 2013; Paoletti et al. 2013).”
BackgroundResultLingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · cited 2×
“Side-eGect assessments included the Simpson-Angus Rating Scale (Simpson and Angus 1970) for extrapyramidal side effects, the Abnormal Involuntary Movement Scale (AIMS) for dyskinesia (Guy 1976), the Barnes Akathisia Scale (Barnes 1989) and Udvalg for Kliniske Undersogelser (UKU) Side-effects Rating Scale (Lingjærde et…”
BackgroundMethodMillan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.023 · Cited by 919 · cited 5×
“Further trials which refer to the normative data for Chinese version of MCCB should be encouraged.”
MethodInfluentialThe MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S. E., Mesholam-Gately, R., Mintz, J., Seidman, L. J., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010043 · Cited by 744
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322 · cited 3×
“…of the role of N-methyl-D-aspartate receptor (NMDA) receptors in the cognition and pathophysiology of schizophrenia (Krystal et al. 1994; Sawa 2009; Javitt et al. 2012; Errico et al. 2013) suggests that enhancement of the NMDA receptor function may improve the cognitive impairment of schizophrenia…”
BackgroundResult
Cited by
d-glutamate and Gut Microbiota in Alzheimer’s Disease
Chang, C.-H., Lin, C.-H., & Lane, H.-Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082676 · Cited by 191
Self-citationKantrowitz, J. T., Epstein, M. L., Lee, M., Lehrfeld, N., Nolan, K. A., Shope, C., Petkova, E., Silipo, G., & Javitt, D. C. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.027 · Cited by 123
Livingston, N. R., Hawkins, P. C., Gilleen, J., Ye, R., Valdearenas, L., Shergill, S. S., & Mehta, M. A. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211000778 · Cited by 17
“Drugs which indirectly enhance NMDA receptor function (and consequently increase cAMP), such as sodium benzoate, have previously been shown to improve cognitive deficits in patients with schizophrenia (Lane et al., 2013; Lin et al., 2017), emphasising the potential utility of other drugs that elevate cAMP, such as PDE…”
Background
Metadata
- Authors
- Lin, C.-Y., Liang, S.-Y., Chang, Y.-C., Ting, S.-Y., Kao, C.-L., Wu, Y.-H., Tsai, G. E., & Lane, H.-Y.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2015-12-22
- Volume
- 18
- Issue
- 5
- Pages
- 357-368
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2220902674
- Cited by
- 96
- References
- 13
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.3109/15622975.2015.1117654
- The paper
- Lin, C.-Y., Liang, S.-Y., Chang, Y.-C., Ting, S.-Y., Kao, C.-L., Wu, Y.-H., Tsai, G. E., & Lane, H.-Y. (2017). Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. The World Journal of Biological Psychiatry. https://doi.org/10.3109/15622975.2015.1117654
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.